NO-donating aspirin inhibits the activation of NF-κB in human cancer cell lines and min mice

Carcinogenesis

Volumn 29, Issue 2, 2008, Pages 390-397

  Williams, Jennie L ^a   Ji, Ping ^a   Ouyang, Nengtai ^a   Liu, Xiaoping ^a   Rigas, Basil ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE DONATING ACETYLSALICYLIC ACID; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL GROWTH; CELL STRAIN HCT116; CELL STRAIN HT29; CELL STRAIN MCF 7; CHEMOPROPHYLAXIS; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA BINDING; DRUG EFFICACY; DRUG STRUCTURE; ENZYME INHIBITION; FEMALE; GEL MOBILITY SHIFT ASSAY; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC 50; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; IN VIVO STUDY; INTESTINE CANCER; INTESTINE EPITHELIUM; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; ASPIRIN; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; KINETICS; MICE; MICE, TRANSGENIC; NF-KAPPA B; NF-KAPPA B P50 SUBUNIT; NITRIC OXIDE; TRANSCRIPTION FACTOR RELA;

EID: 40549088542     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm275     Document Type: Article

References (35)

1. Gustin,D.M. et al. (2002) Chemoprevention of colon cancer: current status and future prospects. Cancer Metastasis Rev., 21, 323-348.
2. Brenner,D.E. et al. (2005) Cancer chemoprevention: lessons learned and future directions. Br. J. Cancer, 93, 735-739.
3. Baron,J.A. (2003) Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog. Exp. Tumor Res., 37, 1-24.
4. Bjorkman,D.J. (1999) Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: risk factors and frequency of complications. Am. J. Med., 107, 3S-8Sdiscussion 8S-10S.
5. Konturek,P.C. et al. (2006) NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin. J. Physiol. Pharmacol., 57 (suppl. 12), 15-24.
6. Rao,C.V. et al. (2006) Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol. Cancer Ther., 5, 1530-1538.
7. Williams,J.L. et al. (2001) Nitric oxide-releasing nonsteroidal antiinflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention. Cancer Res., 61, 3285-3289.
8. Kashfi,K. et al. (2002) Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect. J. Pharmacol. Exp. Ther., 303, 1273-1282.
9. Kashfi,K. et al. (2005) Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo. J. Pharmacol. Exp. Ther., 312, 978-988.
10. Williams,J.L. et al. (2003) Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention. Cancer Res., 63, 7613-7618.
11. Pande,V. et al. (2005) NF-kappaB in human disease: current inhibitors and prospects for de novo structure based design of inhibitors. Curr. Med. Chem., 12, 357-374.
12. Fujioka,S. et al. (2003) Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin. Cancer Res., 9, 346-354.
13. Wang,W. et al. (1999) The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin. Cancer Res., 5, 119-127.
14. Ouyang,N. et al. (2006) Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model. Cancer Res., 66, 4503-4511.
15. Penning,T.D. et al. (1997) Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). J. Med. Chem., 40, 1347-1365.
16. Natarajan,K. et al. (1996) Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc. Natl Acad. Sci. USA, 93, 9090-9095.
17. Hirano,H. et al. (1993) Microsequence analysis of the N-terminally blocked proteins immobilized on polyvinylidene difluoride membrane by western blotting. Electrophoresis, 14, 839-846.
18. Sefton,B.M. (ed.) 2005 Labeling Cultured Cells with 32Pi and Preparing Cell Lysates for Immunoprecipitation. JohnWiley & Sons, Inc., New York, NY.
19. Zabel,U. et al. (1993) Nuclear uptake control of NF-kappa B by MAD-3, an I kappa B protein present in the nucleus. EMBO J., 12, 201-211.
20. Chen,W.S. et al. (2001) Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inibited by a COX-2-selective inhibitor, etodolac. Int. J. Cancer, 91, 894-899.
21. Liu,X.H. et al. (1996) Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res., 56, 5125-5127.
22. Tam,W.F. et al. (2001) Cell-specific association and shuttling of Ikappa-Balpha provides a mechanism for nuclear NF-kappaB in B lymphocytes. Mol. Cell. Biol., 21, 4837-4846.
23. Aguilera,C. et al. (2006) Efficient nuclear export of p65-IkappaBalpha complexes requires 14-3-3 proteins. J. Cell Sci., 119, 3695-3704.
24. Lipkin,M. et al. (1999) Preclinical mouse models for cancer chemoprevention studies. Ann. N. Y. Acad. Sci., 889, 14-19.
25. Williams,J.L. et al. (2004) NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/{thorn})) mice. Biochem. Biophys. Res. Commun., 313, 784-788.
26. Karin,M. (2006) Nuclear factor-kappaB in cancer development and progression. Nature, 441, 431-436.
27. Ichikawa,H. et al. (2006) Isodeoxyelephantopin, a novel sesquiterpene lactone, potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis through suppression of nuclear factor-kappaB (nf-kappaB) activation and nf-kappaB-regulated gene expression. Clin. Cancer Res., 12, 5910- 5918.
28. Nair,A.S. et al. (2006) Deguelin, an Akt inhibitor, suppresses IkappaBalpha kinase activation leading to suppression of NF-kappaB-regulated gene expression, potentiation of apoptosis, and inhibition of cellular invasion. J. Immunol., 177, 5612-5622.
29. Rishi,L. et al. (2007) Nitric oxide induces apoptosis in cutaneous T cell lymphoma (HuT-78) by downregulating constitutive NF-kappaB. Biochim. Biophys. Acta., 1770, 1230-1239.
30. Tam,W.F. et al. (2001) IkappaB family members function by different mechanisms. J. Biol. Chem., 276, 7701-7704.
31. Huang,T.T. et al. (2001) Postrepression activation of NF-kappaB requires the amino-terminal nuclear export signal specific to IkappaBalpha. Mol. Cell. Biol., 21, 4737-4747.
32. Nath,N. et al. (2003) Nitric oxide-donating aspirin inhibits beta-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear beta-catenin-TCF association. Proc. Natl Acad. Sci. USA, 100, 12584-12589.
33. Yeh,R.K. et al. (2004) NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property? Biochem. Pharmacol., 67, 2197-2205.
34. Karin,M. et al. (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol., 5, 749-759.
35. Zhang,Z. et al. (2006) NF-kappaB, inflammation and pancreatic carcinogenesis: NF-kappaB as a chemoprevention target (review). Int. J. Oncol., 29, 185-192.